Drug Profile
Research programme: small molecule therapeutics - Alchemia/AstraZeneca
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Alchemia; AstraZeneca
- Class Carbohydrates; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in Australia
- 23 Apr 2013 Early research in Undefined indication in Australia (unspecified route)